News
News
Synthetic protein targets TLR4 within membrane to curb inflammation
Scientists at Scripps Research have engineered a synthetic protein capable of binding to Toll-like receptor 4 within the cell membrane, reducing inflammatory signalling.
Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity
Insilico Medicine has nominated ISM1354, an AI-designed small-molecule GIPR antagonist, as a preclinical candidate for obesity and related metabolic disorders.
AI consortium targets antibody developability prediction with 10,000-sequence dataset
A new industry consortium led by Ginkgo Datapoints and Apheris is assembling a 10,000-antibody dataset to train AI models that can flag developability problems earlier in the drug discovery pipeline.
Mathematical model reveals self-reinforcing mechanism behind HE-S2 ADC cancer therapy
A mathematical model developed by researchers from Mass General Brigham and the University of Cyprus suggests that the experimental immunomodulatory antibody-drug conjugate HE-S2 may become progressively more effective as it reduces tumour size.
New P. vivax vulnerability could prevent liver-stage malaria infection
A newly identified epitope on the circumsporozoite protein of Plasmodium vivax could offer a route to vaccines that prevent liver-stage infection and curb the relapse-driven transmission cycle.
Opinion and interviews
- Previous
- Next
New P. vivax vulnerability could prevent liver-stage malaria infection
A newly identified epitope on the circumsporozoite protein of Plasmodium vivax could offer a route to vaccines that prevent liver-stage infection and curb the relapse-driven transmission cycle.
Three-signal method converts blood B cells into germinal centre-like cells
Researchers at the University of Osaka have developed a streamlined laboratory method that uses just three sequentially delivered signals to convert naive B cells from human blood into cells closely resembling germinal centre B cells.
Menin inhibitor KO-7246 shows β-cell regeneration in preclinical diabetes models
New preclinical data suggests that menin inhibitor KO-7246 can regenerate functional pancreatic β-cells and sustain improvements in blood glucose control across both Type 1 and Type 2 diabetes models.
In vivo CAR T review charts path to off-the-shelf cellular therapy
A review from researchers at Naval Medical University and Shanghai Jiao Tong University examines how engineering CAR T cells directly inside the body could cut manufacturing complexity and expand patient access to cellular immunotherapy.
Brain circuit linking cold exposure to metabolism identified in hypothalamus
Researchers at USF Health have identified a previously unknown brain circuit in the hypothalamus that coordinates eating behaviour, heat production and energy expenditure in response to cold, with implications for obesity and metabolic disease drug discovery.
Mathematical model probes metals’ role in Alzheimer’s plaque formation
A mathematical framework simulates how metals such as copper and zinc interact with amyloid-beta, offering a new computational tool to explore plaque formation and potential therapeutic interventions in Alzheimer’s disease.
Hyperreactive astrocytes identified as key drivers of TSC epilepsy
Researchers at UC Berkeley have used long-term human brain organoids to show that hyperreactive astrocytes may drive the inflammation and seizures associated with tuberous sclerosis complex.
Experimental drug reverses paralysis and vision loss in MS mice
A novel inflammasome inhibitor derived from HIV antivirals has reversed established neurological deficits in a preclinical MS model, raising hopes for a restorative approach to a disease where current therapies focus primarily on relapse prevention.
Vaccine adjuvant AS01 shown to induce trained immunity in monocytes
A preclinical study published in Myeloid Cells reports that AS01, a vaccine adjuvant system, can induce trained immunity in human monocytes and reduce tumour growth in selected mouse cancer models.
Mayo Clinic strategy restores CAR T targets on aggressive thyroid tumours
Mayo Clinic researchers have shown that approved thyroid cancer drugs can restore a key antigen on aggressive tumour cells, making them visible once more to CAR T cells and improving treatment outcomes in preclinical models.
‘Plug-and-play’ CAR T platform enables post-infusion immune cell reprogramming
City of Hope researchers have developed a modular ‘plug-and-play’ CAR T-cell platform that enables post-infusion reprogramming of engineered immune cells, offering a potential solution to treatment resistance driven by tumour evolution.
Oestrogen receptor alpha identified as right ventricle protector in pulmonary hypertension
Scientists at National Jewish Health have identified oestrogen receptor alpha as a potential therapeutic target for preserving right ventricular function in pulmonary hypertension.
Kidney organoids reveal inflammation drives diabetic kidney disease
University of Washington researchers have used stem cell-derived kidney organoids to uncover inflammatory pathways that drive diabetic kidney disease.
What SIRPα reveals about how breast cancer takes hold in the brain
Scientists at Wake Forest University School of Medicine have uncovered a previously unrecognised cancer-intrinsic role for SIRPα in triple-negative breast cancer, linking the cell-surface protein to mitochondrial fission, tumour-cell migration and suppression of the brain’s immune defences.
BCG and immunotherapy combination cuts tuberculosis relapse risk
Combining the BCG vaccine with a B-cell-targeting immunotherapy significantly reduced tuberculosis relapse rates in preclinical models.
Insilico Medicine launches open-source AI longevity research toolkit
Insilico Medicine has published a Cell cover study introducing LongevityBench, a suite of specialised AI models and an autonomous agentic discovery platform.
Big Picture Bio raises £2.2m to develop AI cancer combination therapies
UK-based cancer drug discovery company Big Picture Bio has closed £2.2 million in funding to advance AI-designed combination therapies into laboratory validation, using a generative world model to map complex tumour biology across disease sites and patient subgroups.
Liver cancer organoids used to screen 1,600 potential treatments
Researchers at the University of Basel have screened more than 1,600 compounds using a biobank of 35 hepatocellular carcinoma organoids, identifying drug combinations that show selective anti-tumour activity across biologically diverse liver cancers.
Why researchers are targeting Nav1.7 in the search for longer-lasting pain relief
Humanised antibodies targeting the voltage-gated sodium channel Nav1.7 have demonstrated prolonged suppression of neuropathic pain in a rat model.
Bacterial enzyme found to weaken gut protective hormone signal
A bacterial enzyme produced by Bacteroides vulgatus has been shown to inactivate the intestinal hormone GLP-2, disrupting gut barrier function and aggravating colitis in a preclinical model — with a natural product inhibitor identified as a potential intervention.